• Live-Dead Bacterial Staining Kit: Nanomaterial Assays

  2026-08-19

  The Live-Dead Bacterial Staining Kit combines NucGreen dye and EthD-III to resolve membrane-associated bacterial viability changes in nanomaterial studies. This guide explains how to interpret dual fluorescence, design controls, and avoid mistaking membrane damage for complete biological death.

• Açaí Extracts, Hepatocyte Toxicity, and Drug Interactions

  2026-08-19

  A 2026 study evaluated how chemically distinct açaí extracts affect human hepatocyte viability, cytochrome P450 expression, and key drug transporters. The results distinguish extract-dependent cytotoxicity from enzyme or transporter induction, providing a practical framework for assessing botanical-drug interaction risk.

• Notch Inhibition Re-sensitizes TNBC to Checkpoint Blockade

  2026-08-18

  Shen and colleagues show that suppressing Notch-driven cytokine programs can remodel the triple-negative breast cancer immune microenvironment and make tumors responsive to sequential immune checkpoint blockade. The study links tumor-associated macrophage reduction, cytotoxic T lymphocyte expansion, altered circulating prometastatic signals, and increased PD-L1 in lung metastases to improved control of metastatic disease.

• USP36–Snail1 Signaling in Ribotoxic Stress

  2026-08-18

  The reference study identifies a JNK–USP36–Snail1 pathway that enables solid tumor cells to preserve nucleolar ribosome biogenesis during ribotoxic stress. Its findings explain why homoharringtonine can be effective in leukemia yet comparatively weak against solid tumors, and support combined disruption of ribotoxic-stress signaling and ribosome function as a therapeutic strategy.

• TECPR1 Tubulation Repairs Lysosomes During Energy Crisis

  2026-08-17

  A 2026 Cell Research study identifies TECPR1 as a lysosomal membrane-repair factor that works with PI4P and KIF1A to generate tubules and remove damaged membrane material during energy stress. The findings connect lysosomal repair to lipid-droplet uptake, metabolic adaptation, and liver protection, while providing a reconstituted membrane system for mechanistic study.

• Tacrine Hydrochloride Hydrate: Assay Logic

  2026-08-17

  Tacrine hydrochloride hydrate is more than a historical cholinesterase inhibitor: it is a controlled perturbation tool for dissecting cholinergic signaling, neuroprotection, and assay translation. This guide connects molecular mechanism with practical endpoint selection while defining what the compound can—and cannot—prove in Alzheimer’s disease research.

• 1-methyl Adenosine: Assay Workflows

  2026-08-16

  Turn 1-methyl Adenosine into a practical readout for RNA turnover, cancer metabolism studies, and biomarker discovery. This guide pairs careful sample handling with stable isotope-diluted UHPLC-MS/MS, emphasizing isomer resolution, matrix control, and troubleshooting.

• Irinotecan Workflows for Tumor Microenvironment Assays

  2026-08-15

  Use Irinotecan (CPT-11) as a mechanistic challenge compound for linking topoisomerase I stress to viability, DNA damage, and apoptosis across colorectal cancer models. Matched organoid–stromal assembloids add a practical layer for testing how tumor microenvironment context changes drug sensitivity and resistance.

• Anti-HMGB1 Rabbit Monoclonal Antibody Guide

  2026-08-14

  This guide explains how to use Anti-HMGB1 Rabbit Monoclonal Antibody, SKU MA3057, for HMGB1 detection in Western blot, immunohistochemistry, and flow cytometry workflows. It is a research-use reagent for human, mouse, and rat samples and should not be treated as a diagnostic or therapeutic assay component.

• MG-132 and the m6A–Proteasome Axis

  2026-08-14

  MG-132 is a cell-permeable proteasome inhibitor that can do more than trigger apoptosis: it can help test how m6A-dependent RNA regulation connects to ubiquitin-mediated proteostasis. This article develops an ovarian-aging assay framework grounded in the YTHDF2/UBE3C study while distinguishing mechanistic inference from established evidence.

• 2-APB for Calcium Signaling Workflows

  2026-08-13

  2-APB provides a practical way to separate IP3 receptor-mediated calcium release from downstream store-operated calcium entry and channel effects. This workflow guide combines concentration-aware assay design with reference-study insights for calcium signaling, oxidative injury, and cardiovascular research.

• ATRX Loss Sensitizes Glioma Cells to PDGFR Inhibitors

  2026-08-13

  The reference study identifies ATRX deficiency as a potential biomarker of increased sensitivity to multi-targeted receptor tyrosine kinase and PDGFR inhibitors in high-grade glioma cells. Its combination data further suggest that ATRX status may help interpret RTK inhibitor trials and guide studies combining targeted inhibition with temozolomide.

• Isorhamnetin as a PI3K/Akt Assay Probe

  2026-08-12

  Isorhamnetin is a flavonoid research compound that links PI3K/Akt activation with oxidative stress, endoplasmic reticulum stress, and apoptosis in porcine oocytes. This article translates the reference findings into practical assay decisions while defining the limits of cross-model interpretation.

• Partial BACE Inhibition and Synaptic Transmission

  2026-08-12

  Satir et al. examined whether reducing amyloid-β production through partial β-secretase inhibition disrupts synaptic transmission in primary cortical neurons. Their results indicate that Aβ secretion can fall by up to approximately 50% without measurable synaptic impairment in this model, whereas stronger inhibition reduced both Aβ secretion and synaptic transmission.

• AP-2α Suppresses MGMT in Recurrent GBM

  2026-08-11

  The reference study identifies AP-2α as a transcriptional suppressor of MGMT in recurrent glioblastoma and links this pathway to improved temozolomide-induced DNA damage. Its combination of promoter-mapping assays, resistant glioma models, and intracranial validation provides a mechanistic framework for studying TMZ resistance and MGMT-directed sensitization.

16336 records 1/1090 page Next 12345 下5页 Last page